Accelerating CAR T cell therapy: Lipid nanoparticles speed up manufacturing Image: iStock/Love Employee Accelerating CAR T cell therapy: Lipid nanoparticles speed up manufacturing Penn Engineers have developed a novel method for manufacturing CAR T cells using lipid nanoparticles as delivery vehicles.
Mapping pancreatic cancer to improve immunotherapy Gregory L. Beatty is an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center. (Image: Courtesy of Penn Medicine News) Mapping pancreatic cancer to improve immunotherapy Gregory L. Beatty, an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center, and his team focus on improving immunotherapy for pancreatic cancer.
‘Dual target’ cell therapy appears to shrink brain tumors Image: iStock/Ildar Imashev ‘Dual target’ cell therapy appears to shrink brain tumors Early Penn Medicine trial results show that targeting two tumor-associated proteins in patients with recurrent glioblastoma may be a promising step toward developing cell therapies for solid tumors.
A new strategy to attack aggressive brain cancer shrank tumors in two early tests Penn In the News Associated Press A new strategy to attack aggressive brain cancer shrank tumors in two early tests A clinical trial led by Stephen Bagley of the Perelman School of Medicine suggests that targeting two associated proteins with CAR T cell therapy could be a viable strategy for shrinking brain tumors. ‘Switchable’ bispecific antibodies pave way for safer cancer treatment Bispecific T cell engagers are emerging as a powerful class of immunotherapy to treat cancer but are sometimes hindered by unwanted outcomes, such as on-target, off-tumor toxicity; cytokine release syndrome; and neurotoxicity. Now, researchers Penn researchers have developed a novel “switchable” bispecific T cell engager that mitigates these negative effects by co-opting a drug already approved by the FDA. (Image: iStock / CIPhotos) ‘Switchable’ bispecific antibodies pave way for safer cancer treatment Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy. UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn In the News Philadelphia Inquirer UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn Medicine researchers like Nobel laureate Drew Weissman are leading efforts to develop a vaccine that prevents cancer, with remarks from Susan Domchek of the Basser Center for BRCA and Robert H. Vonderheide of the Abramson Cancer Center. Penn’s BRCA cancer vaccine trial aims to prevent the disease in healthy people Penn In the News Philadelphia Inquirer Penn’s BRCA cancer vaccine trial aims to prevent the disease in healthy people A trial led by Susan Domchek of the Perelman School of Medicine could use a preventive vaccine to protect people with a BRCA gene mutation from cancer. Imaging just one week after starting treatment can predict melanoma response to immunotherapy Image: iStock/gorodenkoff Imaging just one week after starting treatment can predict melanoma response to immunotherapy New Penn Medicine research shows that following a single dose of a particular immunotherapy drug, CT scans “lit up” with metabolic changes in tumors that correlated with longer survival. Secondary cancers following CAR T cell therapy are rare Image: iStock/vitanovski Secondary cancers following CAR T cell therapy are rare A new Penn Medicine analysis shows that the development of any type of second cancer is a rare occurrence, and some of the earliest patients have gone on to experience long-lasting remissions of a decade or more. New AI tool brings precision pathology for cancer into quicker, sharper focus Image: iStock/iLexx New AI tool brings precision pathology for cancer into quicker, sharper focus Researchers at Penn Medicine have developed an artificial intelligence tool to quickly analyze gene activities in medical images and provide single-cell insight into diseases in tissues and tissue microenvironments. Load More
‘Switchable’ bispecific antibodies pave way for safer cancer treatment Bispecific T cell engagers are emerging as a powerful class of immunotherapy to treat cancer but are sometimes hindered by unwanted outcomes, such as on-target, off-tumor toxicity; cytokine release syndrome; and neurotoxicity. Now, researchers Penn researchers have developed a novel “switchable” bispecific T cell engager that mitigates these negative effects by co-opting a drug already approved by the FDA. (Image: iStock / CIPhotos) ‘Switchable’ bispecific antibodies pave way for safer cancer treatment Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy.
UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn In the News Philadelphia Inquirer UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn Medicine researchers like Nobel laureate Drew Weissman are leading efforts to develop a vaccine that prevents cancer, with remarks from Susan Domchek of the Basser Center for BRCA and Robert H. Vonderheide of the Abramson Cancer Center. Penn’s BRCA cancer vaccine trial aims to prevent the disease in healthy people Penn In the News Philadelphia Inquirer Penn’s BRCA cancer vaccine trial aims to prevent the disease in healthy people A trial led by Susan Domchek of the Perelman School of Medicine could use a preventive vaccine to protect people with a BRCA gene mutation from cancer. Imaging just one week after starting treatment can predict melanoma response to immunotherapy Image: iStock/gorodenkoff Imaging just one week after starting treatment can predict melanoma response to immunotherapy New Penn Medicine research shows that following a single dose of a particular immunotherapy drug, CT scans “lit up” with metabolic changes in tumors that correlated with longer survival. Secondary cancers following CAR T cell therapy are rare Image: iStock/vitanovski Secondary cancers following CAR T cell therapy are rare A new Penn Medicine analysis shows that the development of any type of second cancer is a rare occurrence, and some of the earliest patients have gone on to experience long-lasting remissions of a decade or more. New AI tool brings precision pathology for cancer into quicker, sharper focus Image: iStock/iLexx New AI tool brings precision pathology for cancer into quicker, sharper focus Researchers at Penn Medicine have developed an artificial intelligence tool to quickly analyze gene activities in medical images and provide single-cell insight into diseases in tissues and tissue microenvironments. Load More
Penn’s BRCA cancer vaccine trial aims to prevent the disease in healthy people Penn In the News Philadelphia Inquirer Penn’s BRCA cancer vaccine trial aims to prevent the disease in healthy people A trial led by Susan Domchek of the Perelman School of Medicine could use a preventive vaccine to protect people with a BRCA gene mutation from cancer. Imaging just one week after starting treatment can predict melanoma response to immunotherapy Image: iStock/gorodenkoff Imaging just one week after starting treatment can predict melanoma response to immunotherapy New Penn Medicine research shows that following a single dose of a particular immunotherapy drug, CT scans “lit up” with metabolic changes in tumors that correlated with longer survival. Secondary cancers following CAR T cell therapy are rare Image: iStock/vitanovski Secondary cancers following CAR T cell therapy are rare A new Penn Medicine analysis shows that the development of any type of second cancer is a rare occurrence, and some of the earliest patients have gone on to experience long-lasting remissions of a decade or more. New AI tool brings precision pathology for cancer into quicker, sharper focus Image: iStock/iLexx New AI tool brings precision pathology for cancer into quicker, sharper focus Researchers at Penn Medicine have developed an artificial intelligence tool to quickly analyze gene activities in medical images and provide single-cell insight into diseases in tissues and tissue microenvironments.
Imaging just one week after starting treatment can predict melanoma response to immunotherapy Image: iStock/gorodenkoff Imaging just one week after starting treatment can predict melanoma response to immunotherapy New Penn Medicine research shows that following a single dose of a particular immunotherapy drug, CT scans “lit up” with metabolic changes in tumors that correlated with longer survival.
Secondary cancers following CAR T cell therapy are rare Image: iStock/vitanovski Secondary cancers following CAR T cell therapy are rare A new Penn Medicine analysis shows that the development of any type of second cancer is a rare occurrence, and some of the earliest patients have gone on to experience long-lasting remissions of a decade or more.
New AI tool brings precision pathology for cancer into quicker, sharper focus Image: iStock/iLexx New AI tool brings precision pathology for cancer into quicker, sharper focus Researchers at Penn Medicine have developed an artificial intelligence tool to quickly analyze gene activities in medical images and provide single-cell insight into diseases in tissues and tissue microenvironments.